Press & news

Press releases

Biofidelity Establishes UK Manufacturing Facility

Biofidelity Establishes UK Manufacturing Facility

Sep 10. 2024
Biofidelity is proud to announce the establishment of a manufacturing facility dedicated to genomic assay production in the UK.
Biofidelity announces three senior leadership team appointments

Biofidelity announces three senior leadership team appointments

Sep 4. 2024
Chief Operating Officer, Vice President of People and Chief Financial Officer will contribute to Biofidelity’s growth and people priorities.
Biofidelity to present ASPYRE®-Lung data at AACR 2024

Biofidelity to present ASPYRE®-Lung data at AACR 2024

Apr 5. 2024
Biofidelity announced that new data from its breakthrough product ASPYRE-Lung will be presented in three scientific posters, including a Late Breaking Abstract (LBA) at AACR 2024.
View all press releases

News

Biofidelity’s $24m boost is set to reframe diagnostic testing for lung cancer

Biofidelity’s $24m boost is set to reframe diagnostic testing for lung cancer

Apr 12. 2024
Biofidelity’s successful $24million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing ASPYRE-Lung genomic testing protocol.
Biofidelity Highlights Consistency, Accessibility of Lung Cancer Mutation Assay

Biofidelity Highlights Consistency, Accessibility of Lung Cancer Mutation Assay

Apr 12. 2024
Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types of its ASPYRE-Lung cancer mutation detection assay compared to nextgeneration sequencing (NGS).
Research Triangle-based Biofidelity raises $24 million

Research Triangle-based Biofidelity raises $24 million

Apr 5. 2024
Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.
View all news articles